A Pilot Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment
Phase 1
Not yet recruiting
- Conditions
- Post COVID-19 Cognitive Impairment
- Interventions
- Device: Vielight Neuro RX Gamma sham deviceDevice: Vielight Neuro RX Gamma active device
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Vielight Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05857124
- Locations
- 🇺🇸
Ascada Research, Fullerton, California, United States
Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms
Not Applicable
- Conditions
- COVID-19
- Interventions
- Device: Vielight RX Plus
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Vielight Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT04418505
- Locations
- 🇺🇸
Progressive Medical Research, Port Orange, Florida, United States
🇨🇦Dr. Michael Zahavi, Oshawa, Ontario, Canada
Neuro RX Gamma - Pivotal Phase
Not Applicable
Suspended
- Conditions
- Alzheimer Disease
- Interventions
- Device: Active Neuro RX Gamma deviceDevice: Sham Neuro RX Gamma device
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Vielight Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03484143
- Locations
- 🇺🇸
Headlands Research Orlando, Orlando, Florida, United States
🇨🇦Bruyère Research Institute, Ottawa, Ontario, Canada
🇨🇦True North Clinical Research, Halifax, Nova Scotia, Canada
Vielight Neuro RX Gamma - Feasibility Pilot
Not Applicable
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Device: Neuro RX Gamma asynchronousDevice: Neuro RX Gamma synchronousDevice: Sham
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Vielight Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03328195
- Locations
- 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath